A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis

Kidney International

Volumn 65, Issue 3, 2004, Pages 1064-1075

  Prinsen, Berthil H C M T ^b   Rabelink, Ton J ^b   Romijn, Johannes A ^b   Bisschop, Peter H ^b   De Barse, Martina M J ^b   De Boer, José ^b   Van Haeften, Timon W ^b   Barrett, P Hugh R ^b   Berger, Ruud ^b   De Sain Van Der Velden, Monique G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

apoB100; Cholesterol; De novo lipogenesis; Dyslipidemia; ESRD; Free fatty acids; Insulin; Lipoproteins; Peritoneal dialysis; Stable isotopes; Triglycerides; VLDL

Indexed keywords

APOLIPOPROTEIN B100; FATTY ACID; ISOTOPE; VERY LOW DENSITY LIPOPROTEIN;

ANALYSIS OF VARIANCE; ARTICLE; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; IN VIVO STUDY; INSULIN SENSITIVITY; ISOTOPE LABELING; KIDNEY FAILURE; LIPID ANALYSIS; LIPID METABOLISM; LIPOGENESIS; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION;

EID: 10744231893     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00466.x     Document Type: Article

References (52)

1. BAIGENT C, BURBURY K, WHEELER D: Premature cardiovascular disease in chronic renal failure. Lancet 356:147-152, 2000
2. LEVIN A, FOLEY RN: Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36:S24-S30, 2000
3. Ozsov RC, KASTELEIN JJ, ARISZ L, KOOPMAN MG: Atorvastatin and the dyslipidemia of early renal failure. Atherosclerosis 166:187-194, 2003
4. JUNGERS P, MASSY ZA, KHOA TN, et al: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 1.2:2597-2602, 1997
5. WEBB AT, REAVELEY DA, DONNELL M, et al: Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10:354-357, 1995
6. DEIGHAN CJ, CASLAKE MJ, MCCONNELL M, et al: Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35:852-362, 2000
7. ATTMAN PO, SAMUELSSON OG, MOBERLY J, et al: Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis. Kidney Int 55:1536-1542, 1999
8. ATTMAN PO, SAMUELSSON O, JOHANSSON AC, et al: Dialysis modalities and dyslipidemia. Kidney Int 63 (Suppl 84):S110-S112, 2003
9. FALLER B, LAMEIRE N: Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant 9:280-286, 1994
10. LITTLE J, PHILLIPS L, RUSSELL L, et al: Longitudinal lipid profiles on CAPD: Their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol 9:1931-1939, 1998
11. SAVDIE E, GIBSON JC, CRAWFORD GA, et al: Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia. Kidney Int 18:774-782, 1980
12. ATTMAN PO, GUSTAFSON A: Lipid and carbohydrate metabolism in uraemia. Eur J Clin Invest 9:285-291, 1979
13. CHAN PC, PERSAUD J, VARGHESE Z, et al: Apolipoprotein B turnover in dialysis patients: Its relationship to pathogenesis of hyperlipidemia. Clin Nephrol 31:88-95, 1989
14. VERSCHOOR L, LAMMERS R, BIRKENHAGER JC: Triglyceride turnover in severe chronic non-nephrotic renal failure. Metabolism 27:879-883, 1978
15. PRINSEN BH, DE SAIN-VAN DER VELDEN MG, DE KONING EJ, et al: Hypertriglyceridemia in patients with chronic renal failure: Possible mechanisms. Kidney Int 63(Suppl 84):S121-S124, 2003
16. CHENG SC, CHU TS, HUANG KY, et al: Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int 21:282-289, 2001
17. DEFRONZO RA, ALVESTRAND A, SMITH D, et al: Insulin resistance in uremia. J Clin Invest 67:563-568, 1981
18. EIDEMAK I, FELDT-RASMUSSEN B, KANSTRUP IL, et al. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 38:565-572, 1995
19. LEWIS GF: Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8:146-153, 1997
20. LINDHOLM B, NORBECK HE: Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 220:143-151, 1986
21. BLUMENKRANTZ MJ, GAHL GM, KOPPLE JD, et al: Protein losses during peritoneal dialysis. Kidney Int 19:593-602, 1981
22. KAGAN A, BAR-KHAYIM Y, SCHAFER Z, FAINARU M: Kinetics of peritoneal protein loss during CAPD: I, Different characteristics for low and high molecular weight proteins. Kidney Int 37:971-979, 1990
23. SAKU K, SASAKI J, NAITO S, ARAKAWA K: Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron 51:220-224, 1989
24. DE SAIN-VAN DER VELDEN MG, KAYSEN GA, BARRETT HA, et al: Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53:994-1001, 1998
25. WEINTRAUB M, BURSTEIN A, RASSIN T, et al. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42:1247-1252, 1992
26. BISSCHOP PH, ACKERMANS MT, ENDERT E, et al. The effect of carbohydrate and fat variation in euenergetic diets on postabsorptive free fatty acid release. Br J Nutr 87:555-559, 2002
27. SLOOTER AJ, VAN GOOL WA, VAN DUIJN CM: The role of apolipoproteins E genotyping in the differential diagnosis of dementia. Ned Tijdschr Geneeskd 140:2073-2076, 1996
28. DE SAIN-VAN DER VELDEN MG, KAYSEN GA, DE MEER K, et al. Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: Measurements with stable isotopes. Kidney Int 53:181-188, 1998
29. PRINSEN BH, ROMIJN JA, BISSCHOP PH, et al. Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. J Lipid Res 44:1341-1348, 2003
30. DE SAIN-VAN DER VELDEN MG, REIJNGOUD DJ, KAYSEN GA, et al. Evidence for increased synthesis of lipoprotein[a] in the nephrotic syndrome. J Am Soc Nephrol 9:1474-1481, 1998
31. 13C] valine and isotope ratio mass spectrometry. Anal Biochem 265:308-312, 1998
32. PRINSEN BH, DE SAIN-VAN DER VELDEN MG, KAYSEN GA, et al. Transferrin synthesis is increased in nephrotic patients insufficiently to replace urinary losses. J Am Soc Nephrol 12:1017-1025, 2001
33. HURLEY PJ: Red cell and plasma volumes in normal adults. J Nucl Med 16:46-52, 1975
34. CHRISTIE WW: Lipid Analysis (2nd ed), New York, Pergammon Press, 1982, pp 52-53
35. HELLERSTEIN MK, CHRISTIANSEN M, KAEMPFER S, et al. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest 87:1841-1852, 1991
36. NEESE RA, FAIX D, KLETKE C, et al. Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA. Am J Physiol 264:E136-E147, 1993
37. INGALLS ST, KRIARIS MS, XU Y, et al. Method for isolation of non-esterified fatty acids and several other classes of plasma lipids by column chromatography on silica gel. J Chromatogr 619:9-19, 1993
38. INGALLS ST, XU Y, HOPPEL CL: Determination of plasma non-esterified fatty acids and triglyceride fatty acids by gas chromatography of their methyl esters after isolation by column chromatography on silica gel. J Chromatogr B Biomed Appl 666:1-12, 1995
39. MILES JM, ELLMAN MG, MCCLEAN KL, JENSEN MD: Validation of a new method for determination of free fatty acid turnover. Am J Physiol 252:E431-E438, 1987
40. STEELE R: Influences of glucose loading and of injected insulin or hepatic glucose output. Ann NY Acad Sci 82:420-430, 1959
41. DEURENBERG P, WESTSTRATE JA, SEIDELL JC: Body mass index as a measure of body fatness: Age-and sex-specific prediction formulas. Br J Nutr 65:105-114, 1991
42. MALMSTROM R, PACKARD CJ, WATSON TD, et al: Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454-1464, 1997
43. LEWIS GF, STEINER G: Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 19:390-393, 1996
44. CUMMINGS MH, WATTS GF, PAL C, et al: Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: A stable isotope study. Clin Sci(Lond) 88:225-233, 1995
45. DELARUE J, MAINGOURD C, LAMISSE F, et al. Glucose oxidation after a peritoneal and an oral glucose load in dialyzed patients. Kidney Int 45:1147-1152, 1994
46. HARTY J, CONWAY L, KEEGAN M, et al. Energy metabolism during CAPD: A controlled study. Adv Perit Dial 11:229-233, 1995
47. CHAN MK, PERSAUD J, VARGHESE Z, MOORHEAD JF: Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 25:812-818, 1984
48. DEIGHAN CJ, CASLAKE MJ, MCCONNELL. M, et al: Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL-1. Kidney Int 58:1238-1246, 2000
49. MOBERLY JB, ATTMAN PO, SAMUELSSON O, et al. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 22:220-228, 2002
50. KAYSEN GA, SCHOENFELD PY: Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 25:107-114, 1984
51. PRINSEN BH, RABELINK TJ, BEUTLER JJ, et al. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int 64:1495-1504, 2003
52. HÖRKKÖ S, HUTTUNEN K, KESANIEMI YA: Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 47:1732-1740, 1995